Thank you for the question. I can take that one.
No, Canada has not been relying on that specific vaccine candidate to meet the target of donating the equivalent of 200 million vaccines to COVAX by the end of 2022. As I mentioned, a key, necessary step for COVAX to add a vaccine to its portfolio is WHO EUL recognition, which, as you've noted, is likely not to be the case for Medicago.
I would simply add that countries are free to make whatever procurement and regulatory decisions they deem appropriate. The WHO's emergency use listing is an important step for COVAX, but other countries globally have their own regulator approaches and may make similar decisions to Canada in terms of providing regulatory approval for a vaccine candidate.